Trial intelligence / Profile preview

Disitamab vedotin + toripalimab with or without XELOX versus XELOX for perioperative treatment of HER2-expressing resectable locally advanced gastric or gastroesophageal junction adenocarcinoma

CTR20233553Phase 2Active

Sponsor

RemeGen

Start

Dec 2023

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules

Countries

1